Media stories about Orthofix International N.V. (NASDAQ:OFIX) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orthofix International N.V. earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 48.7326718924013 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Orthofix International N.V. (OFIX) Expected to Post Earnings of $0.41 Per Share (americanbankingnews.com)
- FY2019 EPS Estimates for Orthofix International N.V. (OFIX) Raised by Analyst (americanbankingnews.com)
- Research Analysts Issue Forecasts for Orthofix International N.V.’s Q1 2018 Earnings (NASDAQ:OFIX) (americanbankingnews.com)
- Orthofix International N.V. (NASDAQ:OFIX) to Post FY2018 Earnings of $1.70 Per Share, Gabelli Forecasts (americanbankingnews.com)
- Jefferies Group LLC Reaffirms “Buy” Rating for Orthofix International N.V. (OFIX) (americanbankingnews.com)
Orthofix International N.V. (OFIX) opened at 46.95 on Friday. The company has a 50 day moving average price of $45.66 and a 200-day moving average price of $40.89. Orthofix International N.V. has a 52 week low of $32.51 and a 52 week high of $49.60. The company has a market capitalization of $853.08 million, a P/E ratio of 109.95 and a beta of 0.25.
Orthofix International N.V. (NASDAQ:OFIX) last released its quarterly earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.01. The firm had revenue of $108.90 million for the quarter, compared to analysts’ expectations of $102.94 million. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.41 earnings per share. On average, equities analysts anticipate that Orthofix International N.V. will post $1.55 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on OFIX. Zacks Investment Research downgraded Orthofix International N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Langenberg & Company reissued a “buy” rating and issued a $53.25 price objective on shares of Orthofix International N.V. in a research note on Wednesday, June 14th. Jefferies Group LLC reissued a “buy” rating and issued a $55.00 price objective (up from $50.00) on shares of Orthofix International N.V. in a research note on Thursday. BidaskClub downgraded Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, BTIG Research assumed coverage on Orthofix International N.V. in a research note on Wednesday, June 21st. They issued a “buy” rating and a $52.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Orthofix International N.V. presently has a consensus rating of “Buy” and an average target price of $52.75.
WARNING: This story was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://transcriptdaily.com/2017/08/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-orthofix-international-n-v-nasdaqofix-stock-price.html.
About Orthofix International N.V.
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.